8 years ago The UK Cystic Fibrosis Gene Therapy Consortium, Boehringer Ingelheim, Imperial Innovations and Oxford BioMedica Announce New Partnership to Develop First-In-Class Gene Therapy for Cystic Fibrosis
8 years ago Flutterby Fundraisers to Sponsor Consortium Scientist
8 years ago New Publication - Gelinas et al 2017 - Media Supplements to Improve Lentiviral Vector Production Yields
9 years ago Gene Therapy Funding Update
9 years ago Consortium Student Live Facebook Interview from ASGCT
9 years ago
New Publication Describes Consortium Mixing Device
Friday, September 10th 2010
A novel mixing device for the reproducible generation of nonviral gene therapy formulations, Davies et al., Biotechniques, 49, 666-668. A new publication by Davies et al, describes the development of a new mixing device to be used in out clinical trial programme.
The device, designed in house by the Consortium solves a major issue with the production of pDNA/GL67 liposomes, in that previously we have not had a standardised protocol for mixing the two components. Now with this simple gas driven device we can reproducibly produce formulations in a simple manner.
What is Gene Therapy? (2008): CF gene therapy aims to insert a fully functional CFTR gene into the lung airway cells of people with the condition. Two main types of vector are used to deliver this new copy of the gene. A viral vector, engineered from viral particles or non-viral vectors, plasmid DNA molecules condensed by other chemical entities. More...
